• François Vincent, Marcio Soares, Djamel Mokart, Virginie Lemiale, Fabrice Bruneel, Marouane Boubaya, Frédéric Gonzalez, Yves Cohen, Elie Azoulay, Michaël Darmon, and GrrrOH: Groupe de recherche respiratoire en réanimation en Onco-Hématologie (Group for respiratory research in intensive care in Onco-Hematology, http://www.grrroh.com/).
• Medical-Surgical Intensive Care Unit, Le Raincy-Montfermeil General Hospital, 10, rue du Général Leclerc, 93370, Montfermeil, France. frncsvncnt@aol.com.
• Ann Intensive Care. 2018 Mar 27; 8 (1): 40.

ObjectivesTo assess outcomes at hospital discharge and day-120 after intensive care unit (ICU) discharge among patients with solid cancer admitted to ICU and to identify characteristics associated with in-hospital and day-120 after ICU discharge mortalities.DesignInternational, multicenter, retrospective study.SettingFive ICUs in France and Brazil, two located in cancer centers, two in university affiliated and one in general hospitals.PatientsConsecutive patients aged > 18 years, with underlying solid cancers (known before admission to the ICU or diagnosed during the stay in the ICU), admitted to the participating ICUs and discharged alive from the ICU from January 2006 to December 2011 were included in this study. Patients admitted after scheduled surgery or to secure procedure were excluded. Variables of interest were in-hospital and day-120 post-ICU mortality among patients discharged alive from the ICU.InterventionsNone.Measurements And ResultsA total of 1053 patients aged 63 years (54-71) (median [IQR]) were included. Most of the patients were of the male gender (66.8%). The in-ICU, in-hospital, and four-month post-ICU discharge mortalities were, respectively, 41.3, 60.7, and 65.8%. Among patients discharged alive from the ICU, in multivariate analysis, factors associated with four months post-ICU discharge mortality were type of cancer (OR from 0.25 to 0.52 when compared to lung cancers), systemic extension of the disease (OR 2.54; 95% CI 1.87-3.45), need for invasive mechanical ventilation (OR 2.54; 95% CI 1.80-3.59), for vasopressors (OR 2.35; 95% CI 1.66-3.29), or renal replacement therapy (OR 1.54; 95% CI 0.99-2.38). A predictive score, "Oncoscore," was built performing fairly in predicting 4 months post-ICU discharge outcome (AUC 0.74; 95% CI 0.71-0.77).ConclusionDespite the high day-120 mortality following the ICU discharge, our study reports a meaningful medium-term survival rate after the ICU discharge of solid cancer patients. Of utmost importance, the "Oncoscore" must be validated in prospective studies and cannot be used, in its form without external validation, for individual decision making. Prospective studies to answer questions not provided by this study are needed, including only patients with solid cancers admitted in the ICU for medical reasons or after emergency surgery.

5 keywords...

hide…